Markets open

Novo Nordisk A/S

NVO · NYSE

Analyst Consensus

Hold

13 analysts

$45

Current

—

Low

$47

Average

—

High

Average target implies +3.71% versus the current price.

The ratings synthesis for NVO has not been generated yet.

Rating Actions

No individual rating actions have been captured for NVOyet. Consensus figures above come from Nasdaq's aggregate feed.

Rating actions are extracted from published reporting. Each row links to its source.

Covering Firms

ARGUS RESEARCH

B OF A GLBL RES

CANTOR FITZGERA

EXANE BNP PARIB

GUGGENHEIM SEC.

HSBC GLOBAL RES

JEFFERIES & CO.

JP MORGAN SECUR

MORGAN STANLEY

SANFORD BERNSTE

STIFEL NICOLAUS

TD COWEN

UBS

Symbol: NVO
Type: Stock
Sector: Health Care
Industry: Biotechnology: Pharmaceutical Preparations
Country: Europe
Exchange: NYSE

Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 66,700 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.